Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1093/rheumatology/keaa403 http://scihub22266oqcxt.onion/10.1093/rheumatology/keaa403 33280011!7719039!33280011     free     free     free Deprecated: Implicit conversion from float 217.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 217.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 217.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 217.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 217.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 217.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 217.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 217.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 217.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Rheumatology+(Oxford) 2020 ; 59 (Suppl5): v69-v81 Nephropedia Template TP {{tp|p=33280011|t=2020. Treating systemic lupus erythematosus in the 21st century: new drugs and new perspectives on old drugs |pdf=|usr=}}{{33280011}} gab.com Text Treating systemic lupus erythematosus in the 21st century: new drugs and new perspectives on old drugs JO: Rheumatology (Oxford) http://www.kidney.de/pget.php?&tw=1&pmid=33280011 #FOAvip Besides treating acute flares, the management of SLE should aim at preventing organ damage accrual and drug-associated harms, improving health-related quality of life and prolonging survival. At present, therapy is based on combinations of antimalarials (mainly HCQ), considered the backbone of SLE treatment, glucocorticoids and immunosuppressive drugs. However, these regimens are not universally effective and a substantial degree of damage can be caused by exposure to glucocorticoids. In this review we provide a critical appraisal of the efficacy and safety of available treatments as well as a brief discussion of potentially novel compounds in patients with SLE. We emphasize the use of methylprednisolone pulses for moderate-severe flares, followed by low-moderate doses of oral prednisone with quick tapering to maintenance doses of </=5 mg/day, as well as the prompt institution of immunosuppressive drugs in the setting of severe disease but also as steroid-sparing agents. Indications for the use of biologic agents, namely belimumab and rituximab, in refractory or organ-threatening disease are also presented. We conclude by proposing evidence- and experience-based treatment strategies tailored to the clinical scenario and prevailing organ involvement that can aid clinicians in managing this complex disease. Twit Text FOAVip Treating systemic lupus erythematosus in the 21st century: new drugs and new perspectives on old drugs ????Rheumatology (Oxford) http://www.kidney.de/pget.php?&tw=1&pmid=33280011 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=33280011 #FOAvip English Wikipedia <ref>{{Cite pmid|33280011}}</ref> Treating systemic lupus erythematosus in the 21st century: new drugs and new perspectives on old drugs #MMPMID33280011 Ruiz-Irastorza G; Bertsias G Rheumatology (Oxford) 2020[Dec]; 59 (Suppl5): v69-v81 PMID33280011show ga Besides treating acute flares, the management of SLE should aim at preventing organ damage accrual and drug-associated harms, improving health-related quality of life and prolonging survival. At present, therapy is based on combinations of antimalarials (mainly HCQ), considered the backbone of SLE treatment, glucocorticoids and immunosuppressive drugs. However, these regimens are not universally effective and a substantial degree of damage can be caused by exposure to glucocorticoids. In this review we provide a critical appraisal of the efficacy and safety of available treatments as well as a brief discussion of potentially novel compounds in patients with SLE. We emphasize the use of methylprednisolone pulses for moderate-severe flares, followed by low-moderate doses of oral prednisone with quick tapering to maintenance doses of |Antibodies, Monoclonal, Humanized/therapeutic use[MESH] |Antimalarials/adverse effects/therapeutic use[MESH] |Glucocorticoids/adverse effects/therapeutic use[MESH] |Humans[MESH] |Immunosuppressive Agents/adverse effects/therapeutic use[MESH] |Lupus Erythematosus, Systemic/*drug therapy[MESH] |Rituximab/therapeutic use[MESH]Treating systemic lupus erythematosus in the 21st century: new drugs a(epmc).pdf DeepDyve Pubget Overpricing